Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.97 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.97 |
| ▸ | HRH1 | P35367 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | ESR1 | P03372 | 1/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.97 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.97 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | HRH2 | P25021 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.97 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL1262758 | 1.00 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL29635996 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL3064 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL29379290 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL36882 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL820421 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL580446 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL4840247 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL9221238 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Tolterodine SCHEMBL617185 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111925294-A | Tolterodine pamoate and preparation method thereof | 济南大学 | 2020-11-13 | — | — | CN | claimed |
| EP-1927585-B1 | METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES | INTERQUIM SA (ES) | 2016-07-27 | — | — | EP | claimed |
| US-20110092738-A1 | PROCESS FOR PREPARING 3,3-DIARYLPROPYLAMINES | MEDICHEM S.A. (ES) | 2011-04-21 | — | — | US | claimed |
| US-20080188684-A1 | PROCESS FOR PREPARING 3,3-DIARYLPROPYLAMINES | MEDICHEM S.A. (ES) | 2008-08-07 | — | — | US | claimed |
| EP-1899293-A2 | PROCESS FOR PREPARING 3,3-DIARYLPROPYLAMINES | Medichem, S.A. (ES) | 2008-03-19 | — | — | EP | claimed |
| WO-2007046001-A2 | PROCESS FOR PREPARING 3,3-DIARYLPROPYLAMINES | MEDICHEM, S.A. (US) | 2007-04-26 | — | — | WO | claimed |
| EP-1603862-A1 | 3,3-DIARYLPROPYLAMINE DERIVATIVES AND PROCESSES FOR ISOLATION THEREOF | Ranbaxy Laboratories Limited (IN) | 2005-12-14 | — | — | EP | claimed |
| WO-2004078700-A1 | 3,3-DIARYLPROPYLAMINE DERIVATIVES AND PROCESSES FOR ISOLATION THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2004-09-16 | — | — | WO | claimed |
| CN-111925294-A | Tolterodine pamoate and preparation method thereof | 济南大学 | 2020-11-13 | — | — | CN | disclosed |
| US-20110092738-A1 | PROCESS FOR PREPARING 3,3-DIARYLPROPYLAMINES | MEDICHEM S.A. (ES) | 2011-04-21 | — | — | US | disclosed |
| US-7879912-B2 | High purity crystalline racemic tolterodine forms; converting fumarate derivative to hydrogen bromide or tartaric acid salt | MEDICHEM S.A. (ES) | 2011-02-01 | — | — | US | disclosed |
| US-20100189786-A1 | CRYSTALLINE TOLTERODINE TARTARATE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | ZENTIVA K.S. (CZ) | 2010-07-29 | — | — | US | disclosed |
| EP-2054372-A2 | CRYSTALLINE TOLTERODINE TARTARATE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Zentiva, k.s. (CZ) | 2009-05-06 | — | — | EP | disclosed |
| US-20080188684-A1 | PROCESS FOR PREPARING 3,3-DIARYLPROPYLAMINES | MEDICHEM S.A. (ES) | 2008-08-07 | — | — | US | disclosed |
| WO-2005012227-A2 | PROCESS FOR PREPARATION OF 2-(3-DIISOPROPYLAMINO-1-PHENYLPROPYL)-4-HYDROXYMETHYL-PHENOL, A METABOLITE OF TOLTERODINE | RANBAXY LABORATORIES LIMITED (IN) | 2005-02-10 | — | — | WO | disclosed |
| US-20040249211-A1 | PROCESS FOR THE PREPARATION OF TOLTERODINE | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-09 | — | — | US | disclosed |
| US-6822119-B1 | REACTING 3,4-DIHYDRO-6-METHYL-4-PHENYL-2H-BENZOPYRAN-2-ONE WITH DIMETHYL SULFATE USING PHASE TRANSFER CATALYST; DESTERIFICATION, REDUCTION, AMINATION, SULFONATION, DEPROTECTING, DECYCLIZATION, AND SALT FORMATION | RANBAXY LABORATORIES LIMITED (IN) | 2004-11-23 | — | — | US | disclosed |
| WO-2004078700-A1 | 3,3-DIARYLPROPYLAMINE DERIVATIVES AND PROCESSES FOR ISOLATION THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2004-09-16 | — | — | WO | disclosed |
| EP-1419135-A1 | PROCESS FOR THE PREPARATION OF TOLTERODINE | RANBAXY LABORATORIES, LTD. (IN) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014060-A1 | PROCESS FOR THE PREPARATION OF TOLTERODINE | RANBAXY LABORATORIES LIMITED (IN) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189786-A1 | CRYSTALLINE TOLTERODINE TARTARATE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | ABCG2, HTR7, TST | CHRM3 9/4885CHRM2 30/4885CHRM1 31/4885 |
| US-20080188684-A1 | PROCESS FOR PREPARING 3,3-DIARYLPROPYLAMINES | ADRB3, CYP3A43, QDPR | CHRM3 16/4885CHRM2 70/4885CHRM1 59/4885 |
| US-20040249211-A1 | PROCESS FOR THE PREPARATION OF TOLTERODINE | ADRB3, ADRA1B, ADRA2B | CHRM3 74/4885CHRM2 162/4885CHRM1 788/4885 |
| US-20110092738-A1 | PROCESS FOR PREPARING 3,3-DIARYLPROPYLAMINES | ADRB3, CYP3A43, QDPR | CHRM3 16/4885CHRM2 70/4885CHRM1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.